Literature DB >> 3943595

Schistosoma mansoni: killing of transformed schistosomula by the alternative pathway of human complement.

M Marikovsky, F Levi-Schaffer, R Arnon, Z Fishelson.   

Abstract

The interaction of mechanically transformed schistosomula of Schistosoma mansoni with the alternative pathway of human complement was studied in vitro. To detect early changes in transformation, the schistosomula were prepared at a low temperature and used immediately. As shown previously, freshly transformed schistosomula were highly susceptible to killing by normal human serum and by C4-depleted normal human serum. This serum activity was concentration dependent and was markedly reduced on a twofold serum dilution. Upon incubation at 37 C in defined synthetic medium, schistosomula rapidly became refractory to killing by the alternative pathway of complement. After 1 hr of incubation at 37 C, the percentage of schistosomula which were resistant to killing increased from 16 to 85. This conversion was accompanied by a fivefold decrease in deposition of C3b on schistosomula which had been exposed to 37 C for 1 hr and then further incubated with C4-depleted normal human serum. The following events occurred concomitantly during incubation of freshly transformed schistosomula at 37 C with a half-life of 30-60 min: (1) Decrease in activation and consumption of the alternative pathway of complement by schistosomula; (2) appearance of a strong complement consuming activity in the supernatant of incubating schistosomula; and (3) shedding of protein- and carbohydrate-containing substances from the surface of schistosomula into the supernatant. Isolated external membranes of freshly transformed schistosomula consumed the alternative pathway of complement to a greater extent than membranes of schistosomula preincubated in medium at 37 C. The results demonstrate that transformed schistosomula acquire resistance to complement killing via the alternative pathway by shedding complement-activating substances.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943595     DOI: 10.1016/0014-4894(86)90138-4

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  7 in total

Review 1.  Complement evasion by parasites: search for "Achilles' heel".

Authors:  Z Fishelson
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

2.  Loss of complement activation and leukocyte adherence as Nippostrongylus brasiliensis develops within the murine host.

Authors:  Paul R Giacomin; Hui Wang; David L Gordon; Marina Botto; Lindsay A Dent
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

3.  Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin.

Authors:  Jiusheng Deng; Daniel Gold; Philip T LoVerde; Zvi Fishelson
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

4.  On the three-finger protein domain fold and CD59-like proteins in Schistosoma mansoni.

Authors:  Leonardo P Farias; Greice Krautz-Peterson; Cibele A Tararam; Bogar O Araujo-Montoya; Tatiana R Fraga; Henrique K Rofatto; Floriano P Silva; Lourdes Isaac; Akram A Da'dara; R Alan Wilson; Charles B Shoemaker; Luciana C C Leite
Journal:  PLoS Negl Trop Dis       Date:  2013-10-24

5.  Antibody responses to Schistosoma mansoni schistosomula antigens.

Authors:  Moses Egesa; Lawrence Lubyayi; Frances M Jones; Angela van Diepen; Iain W Chalmers; Edridah M Tukahebwa; Bernard S Bagaya; Cornelis H Hokke; Karl F Hoffmann; David W Dunne; Alison M Elliott; Maria Yazdanbakhsh; Shona Wilson; Stephen Cose
Journal:  Parasite Immunol       Date:  2018-10-14       Impact factor: 2.280

Review 6.  Clinical Use of Schistosoma mansoni Antigens as Novel Immunotherapies for Autoimmune Disorders.

Authors:  L Cleenewerk; Johan Garssen; Astrid Hogenkamp
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

Review 7.  Immune Evasion Strategies of Schistosomes.

Authors:  Jacob R Hambrook; Patrick C Hanington
Journal:  Front Immunol       Date:  2021-02-04       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.